EUVIMEDEUVIMED entdecken
Kohortenstudie

Completion Rates for Patients Undergoing Concurrent Chemoradiotherapy for Stage III Nonsmall Cell Lung Cancer and its Importance in the Era of Consolidation Immunotherapy: A Cohort Study

Neil D Wallace, Jing Xie, Marliese Alexander, David Ball, Fiona Hegi-Johnson, Nikki Plumridge, Shankar Siva, Mark Shaw, Susan Harden, Tom John, Ben Solomon, Louis Irving und 3 weitere

Clinical Lung Cancer · 2025

DOI: 10.1016/j.cllc.2025.02.010 ↗

Kurz gefasst

Kohortenstudie in der Zeitschrift Clinical Lung Cancer, 2025. Verfasst von Neil D Wallace und 14 weiteren Autor:innen. Beteiligte Einrichtung: Department of Radiation Oncology, Peter MacCallum Cancer Centre, Melbourne, Victoria, Australia. Electronic address: Neil.wallace@petermac.org. Hauptthemen laut MEDLINE: Carcinoma, Non-Small-Cell Lung, Lung Neoplasms, Chemoradiotherapy, Immunotherapy. Die Arbeit wurde bisher 4-mal zitiert (Crossref) und nennt 19 Literaturangaben.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

BACKGROUND: Definitive concurrent chemoradiotherapy (CRT) is the primary curative-intent treatment option for unresectable locally advanced nonsmall-cell lung cancer (NSCLC). Completion of CRT is generally required for eligibility for consolidation durvalumab, which significantly improves survival. We sought to establish CRT completion rates at a comprehensive cancer center. PATIENTS AND METHODS: 265 patients were treated with concurrent CRT over the decade 2012-2022, during which durvalumab became available. 63% were male, median age was 67, and 91% had performance status 0-1. All patients were recruited into the AURORA prospective cohort study which captured baseline demographics and comorbidities, and prospectively updated treatment and outcome data at subsequent hospital visits. Data were analyzed retrospectively to evaluate CRT completion rates, reasons for noncompletion, and survival outcomes. Survival was also analyzed based on durvalumab availability and administration. RESULTS: CRT was completed as planned by 246/265 (93%) patients. Reasons for noncompletion included treatment related toxicity (n = 6/19), unrelated illnesses (n = 7/19), local disease progression (n = 2/19), and distant progression (n = 4/19). Median overall survival (OS) was 2.2 years (95% CI, 1.7-2.8) for the entire cohort and 1.0 years (95% CI, 0.2-1.5) for those who ceased CRT early. No specific baseline characteristics predicted noncompletion of CRT. Consolidation durvalumab was associated with improved OS (HR 0.39; 95% CI, 0.21-0.72, P = .002). CONCLUSION: With appropriate supportive care, most patients initially considered suitable for CRT could complete it and access consolidation durvalumab. Consolidation durvalumab was associated with improved survival in this "real-world" stage III NSCLC cohort.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Carcinoma, Non-Small-Cell LungLung NeoplasmsChemoradiotherapyImmunotherapyConsolidation ChemotherapyHumansMaleFemaleAgedMiddle AgedRetrospective StudiesNeoplasm StagingCohort StudiesProspective StudiesSurvival RateAged, 80 and overAdultFollow-Up StudiesAntibodies, MonoclonalAntineoplastic Agents, Immunological

Stichwörter der Autor:innen

ChemoradiotherapyConsolidation immunotherapyDurvalumab availability and survivalLocally-advanced NSCLCTreatment completion rates

Substanzen

durvalumabAntibodies, MonoclonalAntineoplastic Agents, Immunological

Autor:innen und Institutionen

  • Department of Radiation Oncology, Peter MacCallum Cancer Centre, Melbourne, Victoria, Australia. Electronic address: Neil.wallace@petermac.org.
  • Centre for Biostatistics and Clinical Trials, Peter MacCallum Cancer Centre, Melbourne, Victoria, Australia.
  • Pharmacy Department, Peter MacCallum Cancer Centre, Melbourne, Victoria, Australia.
  • Department of Radiation Oncology, Peter MacCallum Cancer Centre, Melbourne, Victoria, Australia; The Sir Peter MacCallum Department of Oncology, University of Melbourne, Melbourne, Victoria, Australia.
  • The Sir Peter MacCallum Department of Oncology, University of Melbourne, Melbourne, Victoria, Australia; Department of Medical Oncology, Peter MacCallum Cancer Centre, Melbourne, Victoria, Australia.
  • Department of Respiratory and Sleep Medicine, Royal Melbourne Hospital, Melbourne, Victoria, Australia; Faculty of Medicine, Dentistry, and Health Sciences, University of Melbourne, Melbourne, Victoria, Australia.

Zitieren

APA

Wallace, N. D., Xie, J., Alexander, M., Ball, D., Hegi-Johnson, F., Plumridge, N., Siva, S., Shaw, M., Harden, S., John, T., Solomon, B., Irving, L., Duffy, M., Officer, A., & MacManus, M. (2025). Completion Rates for Patients Undergoing Concurrent Chemoradiotherapy for Stage III Nonsmall Cell Lung Cancer and its Importance in the Era of Consolidation Immunotherapy: A Cohort Study. Clinical Lung Cancer. https://doi.org/10.1016/j.cllc.2025.02.010

Vancouver

Wallace ND, Xie J, Alexander M, Ball D, Hegi-Johnson F, Plumridge N, et al. Completion Rates for Patients Undergoing Concurrent Chemoradiotherapy for Stage III Nonsmall Cell Lung Cancer and its Importance in the Era of Consolidation Immunotherapy: A Cohort Study. Clinical Lung Cancer. 2025. doi:10.1016/j.cllc.2025.02.010

BibTeX
@article{Wallace2025,
  author = {Wallace, Neil D and Xie, Jing and Alexander, Marliese and Ball, David and Hegi-Johnson, Fiona and Plumridge, Nikki and Siva, Shankar and Shaw, Mark and Harden, Susan and John, Tom and Solomon, Ben and Irving, Louis and Duffy, Mary and Officer, Ann and MacManus, Michael},
  title = {Completion Rates for Patients Undergoing Concurrent Chemoradiotherapy for Stage III Nonsmall Cell Lung Cancer and its Importance in the Era of Consolidation Immunotherapy: A Cohort Study},
  journal = {Clinical Lung Cancer},
  year = {2025},
  doi = {10.1016/j.cllc.2025.02.010}
}
Kostenlos starten →